BioCryst Celebrates HAE Patients with HAE Global Walk
May 15 2020 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced
companywide activities in support of
hae day :-)
2020, a global awareness day for hereditary angioedema (HAE).
BioCryst stands in solidarity with the HAE
community by participating in the annual HAE Global Walk. Since
actual community walks cannot currently be organized, BioCryst
employees around the world are joining virtually with others
supporting hae day :-) by logging their steps and
photographing their activities to raise awareness of HAE.
“HAE is a rare genetic disorder that causes
swelling to various parts of the body, and can be fatal when the
swelling affects the throat due to the risk of suffocation,” said
Henrik Balle Boysen, executive vice president and chief operating
officer of HAE International, the international patient
organization leading hae day :-).
“hae day :-) is an important
part of HAE International’s comprehensive global awareness raising
initiative to facilitate faster diagnosis and access to life saving
HAE therapies,” he added.
“We have heard consistently from HAE patients
and their physicians that an oral prophylactic therapy would be
life-changing. With potential approvals of oral, once-daily
berotralstat beginning around the world later this year, and the
exceptional commercial team we are building, BioCryst is excited to
deliver our innovative new therapy to them,” said Charlie Gayer,
chief commercial officer of BioCryst.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs including berotralstat (BCX7353), an oral
treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward-Looking
Statements This press release contains
forward-looking statements, including statements regarding future
results, performance or achievements. These statements involve
known and unknown risks, uncertainties and other factors which may
cause BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: that the ongoing COVID-19 pandemic could
create challenges in all aspects of our business, including without
limitation delays, stoppages, difficulties and increased expenses
with respect to our and our partners’ development, regulatory
processes and supply chains, could negatively impact our ability to
access the capital or credit markets to finance our operations, or
could have the effect of heightening many of the risks described
below or in the documents we file periodically with the Securities
and Exchange Commission; that developing any HAE product candidate
may take longer or may be more expensive than planned; that ongoing
and future preclinical and clinical development of BCX9930, BCX9250
and galidesivir may not have positive results; that BioCryst may
not be able to enroll the required number of subjects in planned
clinical trials of product candidates; that BioCryst may not
advance human clinical trials with product candidates as expected;
that the FDA, EMA, PMDA or other applicable regulatory agency may
require additional studies beyond the studies planned for product
candidates, or may not provide regulatory clearances which may
result in delay of planned clinical trials, or may impose a
clinical hold with respect to such product candidates, or withhold
market approval for product candidates; that actual financial
results may not be consistent with expectations, including that
2020 operating expenses and cash usage may not be within
management's expected ranges. Please refer to the documents
BioCryst files periodically with the Securities and Exchange
Commission, specifically BioCryst’s most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, all of which identify important factors that could cause
the actual results to differ materially from those contained in
BioCryst’s projections and forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024